Search results
Results From The WOW.Com Content Network
A plot of SIDS rate from 1988 to 2006. The Safe to Sleep campaign, formerly known as the Back to Sleep campaign, [1] is an initiative backed by the US National Institute of Child Health and Human Development (NICHD) at the US National Institutes of Health to encourage parents to have their infants sleep on their backs (supine position) to reduce the risk of sudden infant death syndrome, or SIDS.
Willinger was instrumental in the launch of the Back to Sleep awareness campaign in 1994. The Back to Sleep, now called Safe to Sleep, is widely credited with reducing the rate of sudden infant death syndrome (SIDS)-related deaths in the United States by more than half. Willinger retired from NICHD on May 31, 2017. [2]
Although the rate of SIDS has decreased by 50% since the Safe to Sleep campaign started in 1994, [4] an unintended consequence was that babies missed out on the twelve or so hours they used to spend in the prone position while asleep, and there was a sharp increase in plagiocephaly (flat head syndrome) in infants. [2]
Focusing on safe sleep practices for infants is crucial, especially in Indiana, where sleep-related deaths are a leading cause of infant mortality. Ask the Expert: Safe sleep saves babies' lives ...
For premium support please call: 800-290-4726 more ways to reach us
After not receiving recommendation from city staff during an application process, Safe to Sleep could get leftover Springfield ARPA funds.
The American Academy of Pediatrics' Back to Sleep campaign in the mid-1990s recommended that "babies should not sleep for long periods in inclined devices". In babies under one year old, dying during sleep is a leading cause of accidental death. The recommendation that babies sleep flat on their backs, in an empty crib, halved this death rate. [5]
In a January 2016 report, the nonprofit Institute for Safe Medication Practices analyzed more than 1,000 consumer complaints that the FDA had received about Belsomra between February and July 2015—a number the institute described as “substantial.” A large number came from patients who complained that the drug was ineffective.